Special Issue "Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer 2018"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 31 August 2019
Prof. Dr. Carsten Stephan
Department of Urology, Charité-Universitätsmedizin Berlin, Germany
Phone: +49 30 450 515 052
Fax: +49 30 450 515 904
Interests: biomarkers of prostate cancer; artificial neural networks; prostate health index
Prof. Klaus Jung
Department of Urology, Charité University Hospital, 10117 Berlin, Germany
Interests: clinical biochemistry; molecular and biochemical urooncology; RNA and DNA biology; general laboratory medicine
Prostate cancer is the most common cancer in men in the Western world. Therefore, its early diagnosis, which is mainly based on serum prostate-specific antigen (PSA), has especially gained attention in several fields of research. New biomarkers in serum and urine have been described; for example, the prostate health index (PHI) or urinary Prostate cancer gene 3 (PCA3), or others, including several biomarker-based multivariate models. However, not only the diagnosis, but also, more so, the prognosis or further prediction of this very common disease is important to know. Here, several new nucleic acid or protein-based tissue biomarkers have been described. As already described for other types of cancer, individualized medicine, such as theranostics, a combination of diagnostics and therapeutics, has been a new attraction for late stage prostate cancer, including castration resistant prostate cancer. This Special Issue focuses on “Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer”.
We warmly welcome submissions, including original papers and reviews, on this widely-discussed topic.
Prof. Carsten Stephan
Prof. Klaus Jung
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Urinary biomarkers on prostate cancer
- Serum/plasma biomarkers
- Tissue biomarkers (nuleic acid/protein-based)
- Prognostic factors
- Multivariate models
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Tentative title: Precision medicine in prostate cancer: contribution of exosome characterization
Author: José Antonio López-Guerrero
Summary: Exosomes constitute a valuable source of biomarkers in many tumor types, including prostate cancer. The idea of the review would be to depict the state of the art of the potential use of these extracellular vesicles as a source of biomarkers and their potential use as diagnostic or prognostic tools in urine and serum from prostate cancer patients both in localized as in advanced disease.
Title: Jumping On The Bandwagon: A Review on the Versatile Applications of Gold Nanostructures in Prostate Cancer
Authors: Kamil Rahme, Monira Sarkis and Esther Ghanem
Abstract: Prostate cancer (PCa) has remarkably emerged as a prominent disease in the face of the male population. Conventional treatment like prostatectomy or radiation can be curative only if PCa is diagnosed at an early stage. In the field of targeted therapy, a bevy of novel therapeutic approaches have left a landmark in PCa treatment and have proven to extend survival via distinct mode of actions. Nanotherapy has started to take root and has become the hype of the century by virtue of its abundant advantages. Scientists have invested a great deal of interest in the development of gold nanoparticles (AuNPs), in particular, which holds great hope for PCa theranostics. In this article, we present an overview of the studies published after 1998, which involve the use of different functionalized gold nanostructures (Au NSs) to treat and diagnose PCa. Special reference is given to various in-vitro and in-vivo methods employed, to shuttle Au NSs to PCa cells. In the majority of the studies, an enhancement of either detection or treatment of PCa is observed when compared to their non-targeted counterparts. Adopting the use of polymer garnished Au NSs tagged with specific ligands such as antibodies, tea natural extracts, and receptor inhibitors, etc… lie at the heart of events necessary to effectively treat PCa. Future approaches of treatment are dependent on those worthy multifunctional nanoparticles and are dictated by their ability to achieve a more versatile cancer therapeutic approach.
Keywords: Gold nanoparticles; Bioconjugation; theranostics; prostate cancer; in vitro and in vivo studies.